No Data
No Data
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment
Zai Lab (ZLAB) and Innoviva's (INVA) Specialty Therapeutics subsidiary said Monday China's National Medical Products Administration has approved Zai's new drug application for Xacduro, the two firms'
Zai Lab, Innoviva: China Oks XACDURO For Hospital-Acquired, Ventilator-Associated Pneumonia In 18+
Zai Lab And Innoviva Specialty Therapeutics Announce NMPA Approval For XACDURO(R) (Sulbactam-Durlobactam Or SUL-DUR) For Hospital-Acquired And Ventilator-Associated Pneumonia Caused By Acinetobacter Baumannii-Calcoaceticus Complex In China >ZLAB
Zai Lab And Innoviva Specialty Therapeutics Announce NMPA Approval For XACDURO(R) (Sulbactam-Durlobactam Or SUL-DUR) For Hospital-Acquired And Ventilator-Associated Pneumonia Caused By Acinetobacter B
Innoviva Updates Investor Presentation on Website
Innoviva Inc (INVA) Reports First Quarter 2024 Earnings: A Detailed Analysis
Innoviva Q1 EPS $0.46 Beats $0.17 Estimate, Sales $77.50M Beat $68.00M Estimate
Innoviva (NASDAQ:INVA) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.17 by 170.59 percent. This is a 9.52 percent increase over earnings of $0.42 per s
No Data